GGTI-286 is a potent, cell-permeable, and selective inhibitor of GGTase I. This methyl ester derivative of GGTI-287 is about 25-fold more potent than FTI-277 in inhibiting the processing of the geranylgeranylated protein Rap1A. GGTI-286 has also been shown to have a significant antiproliferative effect in human malignant glioma cells. It also selectively antagonizes oncogenic K-Ras4B.
1. Lerner, E C., et al., 1995. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. The Journal of biological chemistry. 270(45): 26770-3. PMID: 7592913
2. Lerner, E C., et al., 1997. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene. 15(11): 1283-8. PMID: 9315095
3. Qian, Y., et al., 1998. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics. Bioorganic & medicinal chemistry. 6(3): 293-9. PMID: 9568283
4. Bredel, M., et al., 1998. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth. Neurosurgery. 43(1): 124-31; discussion 131-2. PMID: 9657198
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.